289 related articles for article (PubMed ID: 22180496)
21. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
22. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
23. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.
Kasparkova J; Fojta M; Farrell N; Brabec V
Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204
[TBL] [Abstract][Full Text] [Related]
24. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Wang B; Qian H; Yiu SM; Sun J; Zhu G
Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
[TBL] [Abstract][Full Text] [Related]
25. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Mello JA; Acharya S; Fishel R; Essigmann JM
Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890
[TBL] [Abstract][Full Text] [Related]
26. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
Graf N; Ang WH; Zhu G; Myint M; Lippard SJ
Chembiochem; 2011 May; 12(7):1115-23. PubMed ID: 21452186
[TBL] [Abstract][Full Text] [Related]
27. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.
Novakova O; Kasparkova J; Malina J; Natile G; Brabec V
Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903
[TBL] [Abstract][Full Text] [Related]
28. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo.
Mello JA; Lippard SJ; Essigmann JM
Biochemistry; 1995 Nov; 34(45):14783-91. PubMed ID: 7578087
[TBL] [Abstract][Full Text] [Related]
29. Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct.
Li MJ; Yang LY
Int J Oncol; 1999 Dec; 15(6):1177-83. PubMed ID: 10568825
[TBL] [Abstract][Full Text] [Related]
30. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
31. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
32. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
Yamada K; Kato N; Takagi A; Koi M; Hemmi H
Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
[TBL] [Abstract][Full Text] [Related]
33. Cellular Recognition and Repair of Monofunctional-Intercalative Platinum--DNA Adducts.
Liu F; Suryadi J; Bierbach U
Chem Res Toxicol; 2015 Nov; 28(11):2170-8. PubMed ID: 26457537
[TBL] [Abstract][Full Text] [Related]
34. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
35. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.
Vaisman A; Masutani C; Hanaoka F; Chaney SG
Biochemistry; 2000 Apr; 39(16):4575-80. PubMed ID: 10769112
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
37. Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells.
Zhu G; Song L; Lippard SJ
Cancer Res; 2013 Jul; 73(14):4451-60. PubMed ID: 23695549
[TBL] [Abstract][Full Text] [Related]
38. Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta.
Bassett E; Vaisman A; Tropea KA; McCall CM; Masutani C; Hanaoka F; Chaney SG
DNA Repair (Amst); 2002 Dec; 1(12):1003-16. PubMed ID: 12531010
[TBL] [Abstract][Full Text] [Related]
39. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.
Woynarowski JM; Chapman WG; Napier C; Herzig MC; Juniewicz P
Mol Pharmacol; 1998 Nov; 54(5):770-7. PubMed ID: 9804612
[TBL] [Abstract][Full Text] [Related]
40. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.
Bassett E; Vaisman A; Havener JM; Masutani C; Hanaoka F; Chaney SG
Biochemistry; 2003 Dec; 42(48):14197-206. PubMed ID: 14640687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
